New 'Off-the-Shelf' cell therapy targets Hard-to-Treat lymphoma
NCT ID NCT06285422
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 38 times
Summary
This early-phase study tests a new treatment called SC262 for people with Non-Hodgkin's lymphoma that has come back or not responded to other therapies. SC262 uses donor immune cells engineered to find and attack cancer cells. The main goal is to check safety and find the right dose, with early signs of effectiveness also tracked. About 6 adults aged 18-80 are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
The University of Kansas Hospital
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.